Statins: A New Approach to Combat Temozolomide Chemoresistance in Glioblastoma Publisher Pubmed



Shojaei S^{1, 2} ; Alizadeh J¹ ; Thliveris J¹ ; Koleini N^{3, 4} ; Kardami E^{1, 3, 4} ; Hatch GM⁵ ; Xu F⁵ ; Hombachklonisch S¹ ; Klonisch T¹ ; Ghavami S^{1, 6, 7}
Source: Journal of Investigative Medicine Published:2018

Abstract

Patients with glioblastoma multiforme (GBM) have an average life expectancy of approximately 15 months. Recently, statins have emerged as a potential adjuvant cancer therapy due to their ability to inhibit cell proliferation and induce apoptosis in many types of cancer. The exact mechanisms that mediate the inhibitory actions of statins in cancer cells are largely unknown. The purpose of this proceeding paper is to discuss some of the known anticancer effects of statins, while focusing on GBM therapy that includes adjunct therapy of statins with chemotherapeutic agents. © 2018 American Federation for Medical Research.